Citation Report
List of articles citing

General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold

DOI: 10.1074/jbc.m806889200
Journal of Biological Chemistry, 2009, 284, 3273-3284.

Source: https://exaly.com/paper-pdf/46606497/citation-report.pdf
Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
372	[The future of antibody fragments, made of a single immunoglobulin domain]. **2009**, 25, 1159-62		2
371	African trypanosomiasis and antibodies: implications for vaccination, therapy and diagnosis. **2009**, 4, 1075-87		22
370	Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. **2009**, 198, 157-74		341
369	Next generation immunotherapeutics--honing the magic bullet. **2009**, 20, 405-11		42
368	Targeting the EGF receptor ectodomain in the context of cancer. **2009**, 13, 1347-61		1
367	Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom. **2009**, 424, 263-72		49
366	Emerging trends in the diagnosis of human African Trypanosomiasis. **2010**, 137, 1977-86		10
365	Nanobodies : proficient tools in diagnostics. **2010**, 10, 777-85		63
364	High-level expression of Camelid nanobodies in Nicotiana benthamiana. **2010**, 19, 575-86		30
363	In vitro antiviral activity of single domain antibody fragments against poliovirus. **2010**, 87, 257-64		32
362	Isolation and optimization of camelid single-domain antibodies: Dirk Saerens' work on nanobodies. **2010**, 1, 235-8		3
361	High affinity anti-inorganic material antibody generation by integrating graft and evolution technologies: potential of antibodies as biointerface molecules. *Journal of Biological Chemistry*, **2010**, 285, 7784-93	5.4	24
360	In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. **2010**, 51, 1099-106		89
359	Nanobodies as tools for in vivo imaging of specific immune cell types. **2010**, 51, 782-9		87
358	Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies. **2010**, 25, 1-12		15
357	A novel promiscuous class of camelid single-domain antibody contributes to the antigen-binding repertoire. **2010**, 184, 5696-704		52
356	Dissection of the IgNAR V domain: molecular scanning and orthologue database mining define novel IgNAR hallmarks and affinity maturation mechanisms. **2010**, 400, 155-70		32

355	A bispecific nanobody to provide full protection against lethal scorpion envenoming. **2010**, 24, 3479-89		96
354	Structure and function of immunoglobulins. **2010**, 125, S41-52		895
353	Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. **2011**, 25, 2433-46		195
352	Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein. **2011**, 6, e28309		39
351	Practical issues in ADAMTS13 testing and emerging therapies in thrombotic thrombocytopenic purpura. **2011**, 48, 242-50		6
350	High affinity, developability and functional size: the holy grail of combinatorial antibody library generation. *Molecules*, **2011**, 16, 3675-700	4.8	106
349	ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock. **2011**, 9, 22-31		68
348	Camel nanoantibody is an efficient tool for research, diagnostics and therapy. **2011**, 45, 66-73		29
347	Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by 31 integrase. **2011**, 317, 2630-41		26
346	Engineering antibodies and proteins for molecular in vivo imaging. **2011**, 22, 882-7		39
345	Immuno-imaging using nanobodies. **2011**, 22, 877-81		95
344	Nanobodies : new ammunition to battle viruses. **2011**, 92, 389-407		96
343	Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy. **2011**, 13, 940-8		46
342	Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions. **2011**, 79, 2637-47		80
341	Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. **2011**, 6, 85-92		85
340	Adnectins: engineered target-binding protein therapeutics. **2011**, 24, 3-9		178
339	Bispecific Single Domain Antibodies. **2011**, 101-114		1
338	Development of Cys38 knock-out and humanized version of NbAahII10 nanobody with improved neutralization of AahII scorpion toxin. **2011**, 24, 727-35		27

337	Generation and characterization of non-competitive furin-inhibiting nanobodies. **2012**, 448, 73-82		23
336	Production and properties of single domain antibody fragments. **2012**, 23, 9-13		
335	Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. **2012**, 19, 1133-40		49
334	Antibody fragments as therapeutics. **2012**, 265-595		1
333	[Perspectives of application of recombinant diphtheria toxin derivatives]. **2012**, 38, 639-52		7
332	Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. **2012**, 217, 1266-72		31
331	Engineering aggregation resistance in IgG by two independent mechanisms: lessons from comparison of Pichia pastoris and mammalian cell expression. **2012**, 417, 309-35		39
330	Molecular imaging using Nanobodies: a case study. *Methods in Molecular Biology*, **2012**, 911, 559-67	1.4	13
329	Improvement of single domain antibody stability by disulfide bond introduction. *Methods in Molecular Biology*, **2012**, 911, 399-416	1.4	7
328	Site-specific labeling of his-tagged Nanobodies with □□mTc: a practical guide. *Methods in Molecular Biology*, **2012**, 911, 485-90	1.4	32
327	Single-domain antibody fragments derived from heavy-chain antibodies: a review. **2012**, 57, 439-513		47
326	Engineering aggregation-resistant antibodies. **2012**, 3, 263-86		90
325	Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. **2012**, 45, 399-407		35
324	Nanobody-coupled microbubbles as novel molecular tracer. **2012**, 158, 346-53		70
323	Immunoglobulin domains in Escherichia coli and other enterobacteria: from pathogenesis to applications in antibody technologies. **2013**, 37, 204-50		65
322	Engineered antibody variable and constant domains as therapeutic candidates. **2013**, 2, 637-46		5
321	Single-domain antibody-based and linker-free bispecific antibodies targeting FcRIII induce potent antitumor activity without recruiting regulatory T cells. **2013**, 12, 1481-91		48
320	Atypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural analysis. *Journal of Biological Chemistry*, **2013**, 288, 17408-19	5.4	53

319	Targeting tumors with nanobodies for cancer imaging and therapy. **2013**, 172, 607-17		146
318	Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2). **2013**, 97, 245-54		23
317	Nanobodies: natural single-domain antibodies. **2013**, 82, 775-97		1104
316	Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. **2013**, 97, 318-28		25
315	Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target. **2013**, 13, 1149-60		86
314	Nanobodies and their potential applications. **2013**, 8, 1013-26		183
313	Novel therapy based on camelid nanobodies. **2013**, 4, 1321-36		28
312	Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments. **2013**, 4, 73-84		35
311	Contributions of the complementarity determining regions to the thermal stability of a single-domain antibody. **2013**, 8, e77678		25
310	Human recombinant domain antibodies against multiple sclerosis antigenic peptide CSF114(Glc). **2014**, 27, 618-26		3
309	A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. **2014**, 210, 964-72		57
308	GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics. **2014**, 35, 247-55		64
307	A robust pipeline for rapid production of versatile nanobody repertoires. **2014**, 11, 1253-60		253
306	Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies. **2014**, 71, 301-35		44
305	Chaperone nanobodies protect gelsolin against MT1-MMP degradation and alleviate amyloid burden in the gelsolin amyloidosis mouse model. **2014**, 22, 1768-78		26
304	Single-Domain Antibodies: An Overview. **2014**, 311-340		
303	Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging. *Bioconjugate Chemistry*, **2014**, 25, 979-88	6.3	103
302	Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. **2014**, 11, 1939-54		70

301	Characteristics of the somatic hypermutation in the Camelus dromedarius T cell receptor gamma (TRG) and delta (TRD) variable domains. **2014**, 46, 300-13		28
300	Nanobody: the "magic bullet" for molecular imaging?. **2014**, 4, 386-98		167
299	Antibody Libraries from Immunized Repertoires. **2015**, 390-471		
298	Single-domain antibodies: building blocks for multifunctional biologics. **2015**, 122-134		
297	Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo. **2015**, 282, 3618-31		8
296	Blocking of Histamine Release and IgE Binding to FcεRI on Human Basophils by Antibodies Produced in Camels. **2015**, 7, 583-9		
295	Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering. **2015**, 84, 1-26		46
294	The use of F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer. **2015**, 1, 142-147		70
293	A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. **2015**, 56, 1094-9		78
292	Stress selections on domain antibodies: 'what doesn't kill you makes you stronger'. **2015**, 28, 59-66		7
291	Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena. **2015**, 111, 82-106		25
290	Nanobody-based cancer therapy of solid tumors. **2015**, 10, 161-74		155
289	Camel milk ameliorates the coagulopathy in streptozotocin diabetic rat model. **2015**, 68, 79-87		9
288	Fully Human VH Single Domains That Rival the Stability and Cleft Recognition of Camelid Antibodies. *Journal of Biological Chemistry*, **2015**, 290, 11905-17	5.4	40
287	Structural and genetic diversity in antibody repertoires from diverse species. **2015**, 33, 27-41		43
286	Noninvasive imaging of immune responses. **2015**, 112, 6146-51		152
285	Isolation and characterization of antigen-specific alpaca (Lama pacos) VHH antibodies by biopanning followed by high-throughput sequencing. **2015**, 158, 205-15		14
284	A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model. *Journal of Biological Chemistry*, **2015**, 290, 6584-95	5.4	23

283	Energy profile of nanobody-GFP complex under force. **2015**, 12, 056009		9
282	Monitoring liver macrophages using nanobodies targeting Vsig4: concanavalin A induced acute hepatitis as paradigm. **2015**, 220, 200-9		22
281	Generation of a chickenized catalytic anti-nucleic acid antibody by complementarity-determining region grafting. **2015**, 63, 513-20		5
280	An update on antibody-based immunotherapies for Clostridium difficile infection. **2016**, 9, 209-24		16
279	Structure and Function of Camelid VHH. **2016**, 153-159		5
278	Biotechnological Trends in Spider and Scorpion Antivenom Development. **2016**, 8,		37
277	Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?. **2015**, 5,		24
276	Importance of Hypervariable Region 2 for Stability and Affinity of a Shark Single-Domain Antibody Specific for Ebola Virus Nucleoprotein. **2016**, 11, e0160534		9
275	Cross-Neutralising Nanobodies Bind to a Conserved Pocket in the Hemagglutinin Stem Region Identified Using Yeast Display and Deep Mutational Scanning. **2016**, 11, e0164296		13
274	Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities. **2016**, 11, 328-339		76
273	In vivo detection of small tumour lesions by multi-pinhole SPECT applying a (99m)Tc-labelled nanobody targeting the Epidermal Growth Factor Receptor. *Scientific Reports*, **2016**, 6, 21834	4.9	37
272	Nanobodies as therapeutics: big opportunities for small antibodies. *Drug Discovery Today*, **2016**, 21, 1076-113	6.8	221
271	Global analysis of VHHs framework regions with a structural alphabet. **2016**, 131, 11-19		10
270	Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets. **2016**, 243, 1-10		52
269	Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation. **2016**, 8, 366ra162		101
268	Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity. **2016**, 17, 1231-1239		17
267	Molecular dynamics simulations and docking enable to explore the biophysical factors controlling the yields of engineered nanobodies. *Scientific Reports*, **2016**, 6, 34869	4.9	23
266	Specificity Evaluation and Disease Monitoring in Arthritis Imaging with Complement Receptor of the Ig superfamily targeting Nanobodies. *Scientific Reports*, **2016**, 6, 35966	4.9	8

265	Imaging Biomarkers in Immunotherapy. **2016**, 8, 1-13		24
264	A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells. *ChemBioChem*, **2016**, 17, 155-8	3.8	34
263	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. *Journal of Biological Chemistry*, **2016**, 291, 16659-71	5.4	23
262	Bispecific antibodies in cancer immunotherapy. **2016**, 12, 2491-2500		32
261	Ultrasmall inorganic nanoparticles: State-of-the-art and perspectives for biomedical applications. **2016**, 12, 1663-701		178
260	Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. *Nature Communications*, **2016**, 7, 10321	17.4	404
259	Distinct antibody species: structural differences creating therapeutic opportunities. **2016**, 40, 7-13		32
258	Development of high-affinity single chain Fv against foot-and-mouth disease virus. **2016**, 84, 50-5		2
257	Single-domain antibodies for biomedical applications. **2016**, 38, 21-8		49
256	Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis. **2017**, 19, 49-58		19
255	Cytoplasmic versus periplasmic expression of site-specifically and bioorthogonally functionalized nanobodies using expressed protein ligation. **2017**, 133, 25-34		12
254	Ribosome-dependent Vibrio cholerae mRNAse HigB2 is regulated by a β-strand sliding mechanism. **2017**, 45, 4972-4983		25
253	Methods, Tools and Current Perspectives in Proteogenomics. **2017**, 16, 959-981		82
252	Targeted antigen delivery by an anti-class II MHC VHH elicits focused αMUC1(Tn) immunity. **2017**, 8, 5591-5597		20
251	Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38 tumors in mouse models in vivo. *Scientific Reports*, **2017**, 7, 14289	4.9	41
250	A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding. *Scientific Reports*, **2017**, 7, 7438	4.9	11
249	A synthetic library for rapid isolation of humanized single-domain antibodies. **2017**, 22, 239-247		9
248	Screening and antitumor effect of an anti-CTLA-4 nanobody. **2018**, 39, 511-518		16

247	Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer's disease. **2017**, 9, 1016-1027		15
246	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. **2017**, 77, 123-144		4
245	Camelid and shark single domain antibodies: structural features and therapeutic potential. **2017**, 45, 10-16		107
244	Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. **2017**, 12, 1969-1983		42
243	Single Domain Antibodies as New Biomarker Detectors. **2017**, 7,		16
242	Nanobodies As Tools to Understand, Diagnose, and Treat African Trypanosomiasis. *Frontiers in Immunology*, **2017**, 8, 724	8.4	12
241	Enhancing Stability of Camelid and Shark Single Domain Antibodies: An Overview. *Frontiers in Immunology*, **2017**, 8, 865	8.4	44
240	Intracellular Crosslinking of Filoviral Nucleoproteins with Xintrabodies Restricts Viral Packaging. *Frontiers in Immunology*, **2017**, 8, 1197	8.4	12
239	Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy. *Frontiers in Immunology*, **2017**, 8, 1442	8.4	83
238	Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook. *Frontiers in Immunology*, **2017**, 8, 1589	8.4	88
237	Single-Domain Antibodies As Therapeutics against Human Viral Diseases. *Frontiers in Immunology*, **2017**, 8, 1802	8.4	58
236	Exploiting Nanobodies' Singular Traits. **2018**, 36, 695-715		112
235	A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement. *Journal of Biological Chemistry*, **2018**, 293, 6269-6281	5.4	18
234	Exploring the role of post-translational modifications in regulating □synuclein interactions by studying the effects of phosphorylation on nanobody binding. **2018**, 27, 1262-1274		18
233	Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non-Ig scaffolds. **2018**, 38, 1837-1873		7
232	Combinatorial Design of a Nanobody that Specifically Targets Structured RNAs. **2018**, 430, 1652-1670		4
231	Impact in stability during sequential CDR grafting to construct camelid VHH antibodies against zinc oxide and gold. **2018**, 164, 21-25		1
230	Noninvasive PET Imaging of T cells. **2018**, 4, 359-373		63

229	Nanobodys: Strategien zur chemischen Funktionalisierung und intrazelluläre Anwendungen. **2018**, 130, 2336-2357		16
228	Nanobodies: Chemical Functionalization Strategies and Intracellular Applications. **2018**, 57, 2314-2333		118
227	Development of an adenovirus vector vaccine platform for targeting dendritic cells. **2018**, 25, 27-38		19
226	Single-Domain Antibodies or Nanobodies: A Class of Next-Generation Antibodies. **2018**, 37, 316-322		50
225	A Two-Step Approach for the Design and Generation of Nanobodies. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	14
224	Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells. **2018**, 15, 4577-4588		32
223	Novel half-life extended anti-MIF nanobodies protect against endotoxic shock. **2018**, 32, 3411-3422		14
222	The Development of Single Domain Antibodies for Diagnostic and Therapeutic Applications. **2018**,		3
221	Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses. **2018**, 6, 870-880		13
220	A HER2 bispecific antibody can be efficiently expressed in with potent cytotoxicity. **2018**, 16, 1259-1266		10
219	Compact Seahorse-Shaped T´Cell‐Activating Antibody for Cancer Therapy. **2018**, 1, 1700031		3
218	Creating molecules that modulate immune responses. **2018**, 2, 184-193		11
217	Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment. *Frontiers in Immunology*, **2018**, 9, 273	8.4	46
216	Beyond antibody engineering: directed evolution of alternative binding scaffolds and enzymes using yeast surface display. **2018**, 17, 32		36
215	Nanobody Based Dual Specific CARs. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	62
214	Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies. **2018**, 32, 441-464		53
213	A review of approaches to F radiolabelling affinity peptides and proteins. **2019**, 62, 4-23		22
212	Nanobodies that Neutralize HIV. **2019**, 7,		15

211	Nanobodies and Their In Vivo Applications. **2019**, 263-277		0
210	Ultrasound Molecular Imaging of Atherosclerosis With Nanobodies: Translatable Microbubble Targeting Murine and Human VCAM (Vascular Cell Adhesion Molecule) 1. **2019**, 39, 2520-2530		19
209	Structure and development of single domain antibodies as modules for therapeutics and diagnostics. **2019**, 244, 1568-1576		23
208	Theranostics in immuno-oncology using nanobody derivatives. **2019**, 9, 7772-7791		48
207	Domain swapping of complementarity-determining region in nanobodies produced by Pichia pastoris. *AMB Express*, **2019**, 9, 107	4.1	0
206	Construction of Anti-hPD-L1 HCAb Nb6 and I Labeling for Noninvasive Detection of PD-L1 Expression in Human Bone Sarcoma. *Bioconjugate Chemistry*, **2019**, 30, 2614-2623	6.3	9
205	Development of a Simple Pretreatment Immunoassay Based on an Organic Solvent-Tolerant Nanobody for the Detection of Carbofuran in Vegetable and Fruit Samples. **2019**, 9,		7
204	The Antigenic Topology of Norovirus as Defined by B and T Cell Epitope Mapping: Implications for Universal Vaccines and Therapeutics. **2019**, 11,		12
203	Structural insights into the mechanism of single domain VHH antibody binding to cortisol. **2019**, 593, 1248-1256		7
202	Single-Domain Antibodies Represent Novel Alternatives to Monoclonal Antibodies as Targeting Agents against the Human Papillomavirus 16 E6 Protein. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	6
201	Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. **2019**, 116, 7624-7631		123
200	Nanobody: outstanding features for diagnostic and therapeutic applications. **2019**, 411, 1703-1713		73
199	Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer. **2019**, 8,		60
198	Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination with Photochemical Internalization. **2019**, 16, 1633-1647		38
197	Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies. *Frontiers in Immunology*, **2018**, 9, 3037	8.4	18
196	Nanobodies: The "Magic Bullets" in therapeutics, drug delivery and diagnostics. **2020**, 28, 29-51		35
195	A Novel Nanobody Scaffold Optimized for Bacterial Expression and Suitable for the Construction of Ribosome Display Libraries. **2020**, 62, 43-55		10
194	The Therapeutic Potential of Nanobodies. **2020**, 34, 11-26		206

193	Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	10
192	Physicochemical determinants of antibody-protein interactions. **2020**, 121, 85-114		2
191	Nanobodies as non-invasive imaging tools. **2020**, 7, 2-14		6
190	Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager. **2020**, 8, 1139-1149		13
189	Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. **2020**, 27, 846-854		275
188	Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies. *Frontiers in Immunology*, **2020**, 11, 560244	8.4	2
187	Nanobodies-Useful Tools for Allergy Treatment?. *Frontiers in Immunology*, **2020**, 11, 576255	8.4	2
186	An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. *Nature Communications*, **2020**, 11, 4420	17.4	151
185	NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. **2020**, 12,		19
184	Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform. **2020**, 12, 1812210		10
183	Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. *Nature Communications*, **2020**, 11, 4528	17.4	80
182	Structure- and sequence-based design of synthetic single-domain antibody libraries. **2020**, 33,		5
181	Nanobodies as Versatile Tool for Multiscale Imaging Modalities. **2020**, 10,		6
180	High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. *Scientific Reports*, **2020**, 10, 22370	4.9	46
179	Camelid-derived single-chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications. **2020**, 4, 1087-1110		3
178	Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity. **2020**, 8,		3
177	An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. **2020**, 370, 1473-1479		166
176	Single domain antibody-based vectors in the delivery of biologics across the blood-brain barrier: a review. **2021**, 11, 1818-1828		3

175	Identification of Human Single-Domain Antibodies against SARS-CoV-2. **2020**, 27, 891-898.e5		155
174	PCR-based approach for site-specific conjugation of long double-stranded DNA to a single-domain VHH antibody. **2020**, 168, 63-72		
173	ImmunoPET: Concept, Design, and Applications. **2020**, 120, 3787-3851		98
172	T lymphocyte-targeted immune checkpoint modulation in glioma. **2020**, 8,		15
171	A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system. *Journal of Biological Chemistry*, **2020**, 295, 8746-8758	5.4	7
170	Engineering Stability, Viscosity, and Immunogenicity of Antibodies by Computational Design. **2020**, 109, 1631-1651		19
169	Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
168	Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	23
167	VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis. **2020**, 12, 1709322		12
166	Serum albumin-binding V Hs with variable pH sensitivities enable tailored half-life extension of biologics. **2020**, 34, 8155-8171		12
165	A guide to: generation and design of nanobodies. **2021**, 288, 2084-2102		58
164	A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. **2021**, 35, 1586-1596		17
163	HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1371-1389	8.8	14
162	Transforming nanobodies into high-precision tools for protein function analysis. **2021**, 320, C195-C215		4
161	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. **2021**, 26, 311-329		0
160	Nanobodies: The Future of Antibody-Based Immune Therapeutics. **2021**, 36, 109-122		14
159	Llamanade: An Open-Source Computational Pipeline for Robust Nanobody Humanization.		1
158	Nanobodies as , non-invasive, imaging agents. **2021**, 2, 685-701		6

157	Therapeutic Antibodies Targeting Potassium Ion Channels. **2021**, 267, 507-545		0
156	Nanobodies Provide Insight into the Molecular Mechanisms of the Complement Cascade and Offer New Therapeutic Strategies. **2021**, 11,		1
155	Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy. **2021**, 6, 80		9
154	Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. **2021**, 371,		149
153	The Application of Nanobody in CAR-T Therapy. **2021**, 11,		13
152	Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. **2021**, 10, e12057		27
151	Insights into biological therapeutic strategies for COVID-19. **2021**, 1, 166-178		2
150	Immunogenicity Risk Profile of Nanobodies. *Frontiers in Immunology*, **2021**, 12, 632687	8.4	32
149	Immunogenicity and humanization of single-domain antibodies. **2021**,		15
148	Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody". **2021**, 63, 525-533		2
147	Interaction standards for biophysics: anti-lysozyme nanobodies. **2021**, 50, 333-343		1
146	Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2. **2021**,		4
145	Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma. **2021**, 35, 3002-3006		5
144	Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC. **2021**, 18, 2375-2384		2
143	Designing and constructing a phage display synthesized single domain antibodies library based on camel VHHs frame for screening and identifying humanized TNF-□specific nanobody. **2021**, 137, 111328		3
142	The antigen-binding moiety in the driver's seat of CARs. **2022**, 42, 306-342		3
141	Protein Engineering Strategies for Improved Pharmacokinetics. 2101633		5
140	Recent Advances in the Scaffold Engineering of Protein Binders. **2021**, 22, 878-891		3

139	Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide-Cysteine Chemistry. **2021**, 14,		3
138	Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy. **2021**, 334, 389-412		7
137	Recent advances in antibody-based immunotherapy strategies for COVID-19. **2021**, 122, 1389-1412		9
136	Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralising SARS-CoV-2 nanobodies.		1
135	A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. *Nature Communications*, **2021**, 12, 4635	17.4	15
134	Engineering Antibody-Based Therapeutics: Progress and Opportunities. 317-351		1
133	Pharmacokinetics of Single Domain Antibodies and Conjugated Nanoparticles Using a Hybrid near Infrared Method. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
132	Engineering of single-domain antibodies for next-generation snakebite antivenoms. **2021**, 185, 240-250		2
131	A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer. **2021**, 13,		5
130	: an open-source computational pipeline for robust nanobody humanization. **2021**,		1
129	A resource of high-quality and versatile nanobodies for drug delivery. **2021**, 24, 103014		4
128	Strategic Development of an Immunotoxin for the Treatment of Glioblastoma and Other Tumours Expressing the Calcitonin Receptor. **2021**, 10,		1
127	A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies. **2021**, 9,		0
126	Application of Single-Domain Antibodies ("Nanobodies") to Laboratory Diagnosis. **2021**, 41, 549-558		8
125	Design and construction a novel humanized biparatopic nanobody-based immunotoxin against epidermal growth factor receptor (EGFR). **2021**, 66, 102837		0
124	Effect of Humanizing Mutations on the Stability of the Llama Single-Domain Variable Region. **2021**, 11,		4
123	High-efficacy, high-manufacturability human VH domain antibody therapeutics from transgenic sources. **2021**, 34,		
122	Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor. **2021**, 11,		5

121	Discovery Process for Antibody-Based Therapeutics. **2012**, 9-32		6
120	Isolation of Antigen-Specific VHH Single-Domain Antibodies by Combining Animal Immunization with Yeast Surface Display. *Methods in Molecular Biology*, **2020**, 2070, 173-189	1.4	8
119	The occurrence of three D-J-C clusters within the dromedary TRB locus highlights a shared evolution in Tylopoda, Ruminantia and Suina. **2017**, 76, 105-119		13
118	HRP-conjugated plug-and-playable IgG-binding nanobodies as secondary antibody mimics in immunoassays. **2020**, 320, 128312		8
117	Perspectives on the development of neutralizing antibodies against SARS-CoV-2. **2020**, 3, 109-114		28
116	Fully human single-domain antibodies against SARS-CoV-2.		10
115	Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain.		12
114	An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.		19
113	A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection.		16
112	High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme.		4
111	Single-domain antibodies represent novel alternatives to monoclonal antibodies as targeting agents against the human papillomavirus 16 E6 protein.		1
110	AAV mediated delivery of a novel anti-BACE1 VHH reduces Abeta in an Alzheimer disease mouse model.		3
109	Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments. **2020**, 8, 518-529		24
108	A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. **2012**, 7, e29941		62
107	The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency. **2014**, 9, e103294		18
106	Novel camelid antibody fragments targeting recombinant nucleoprotein of Araucaria hantavirus: a prototype for an early diagnosis of Hantavirus Pulmonary Syndrome. **2014**, 9, e108067		13
105	Llama nanoantibodies with therapeutic potential against human norovirus diarrhea. **2015**, 10, e0133665		26
104	Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. **2018**, 13, e0191024		22

103	Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro. **2017**, 8, 38568-38580		21
102	Engineered Autonomous Human Variable Domains. **2016**, 22, 6527-6537		21
101	Nanobodies: a new approach for the diagnosis and treatment of viral infectious diseases.		9
100	INDI-integrated nanobody database for immunoinformatics. **2021**,		5
99	Camelid Single-Domain Antibodies for Targeting Cancer Nanotheranostics. **2021**, 93-123		1
98	Delicate balance among thermal stability, binding affinity, and conformational space explored by single-domain VH antibodies. *Scientific Reports*, **2021**, 11, 20624	4.9	3
97	Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies. **2021**, 108024		6
96	Functional Hybrid Micro/Nanoentities Promote Agro-Food Safety Inspection. **2021**, 69, 12402-12417		5
95	Monoclonal Antibody Therapy for Cancer. **2011**, 59-83		
94	References. **2012**, 459-595		1
93	Adaptive Immunity and Trypanosomiasis-Driven B-Cell Destruction. **2014**, 115-138		
92	Unraveling the Role of Nanobodies Tetrad on Their Folding and Stability Assisted by Machine and Deep Learning Algorithms. **2020**, 93-104		
91	Eco-compatible Single Format Nanobioantibody. **2020**, 113-125		
90	Noninvasive Immuno-PET Imaging of CD8 T Cell Behavior in Influenza A Virus-Infected Mice. *Frontiers in Immunology*, **2021**, 12, 777739	8.4	1
89	Modern Technologies for Creating Synthetic Antibodies for Clinical application. **2009**, 1, 32-50		23
88	Fingerprint-like Analysis of "Nanoantibody" Selection by Phage Display Using Two Helper Phage Variants. **2010**, 2, 85-93		3
87	Effective Genetic Expression of Nanoantibodies by Recombinant Adenoviral Vector in vitro. **2011**, 3, 64-70		2
86	Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its function. **2018**, 21, 260-266		15

85	Nanobodies as probes and modulators of cardiovascular GPCRs. **2021**,		1
84	Intrabody Targeting HIF-1 Mediates Transcriptional Downregulation of Target Genes Related to Solid Tumors. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
83	Isolation of nanobodies with potential to reduce patients IgE binding to Bet v 1 (68/100 characters). **2021**,		0
82	A Targeted Catalytic Nanobody (T-CAN) with Asparaginolytic Activity. **2021**, 13,		0
81	A comprehensive comparison between camelid nanobodies and single chain variable fragments. *Biomarker Research*, **2021**, 9, 87	8	6
80	A Novel Potent Carrier for Unconventional Protein Export in .. **2021**, 9, 816335		0
79	EGFR-Targeted Photodynamic Therapy.. **2022**, 14,		6
78	Camelization of a murine single-domain antibody against aflatoxin B and its antigen-binding analysis.. **2022**, 38, 51		0
77	Easily Established and Multifunctional Synthetic Nanobody Libraries as Research Tools.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	2
76	Arsenal of Nanobodies for Broad-Spectrum Countermeasures against Current and Future SARS-CoV-2 Variants of Concerns.		0
75	A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. **2021**, 118,		4
74	Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern.. **2021**, e53865		6
73	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. **2021**, 10,		3
72	Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications.. *Methods in Molecular Biology*, **2022**, 2446, 3-17	1.4	0
71	Humanization of Camelid Single-Domain Antibodies.. *Methods in Molecular Biology*, **2022**, 2446, 299-312	1.4	0
70	Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies.. *Science Advances*, **2022**, 8, eabm0220	14.3	1
69	Structural Insights into the Design of Synthetic Nanobody Libraries.. *Molecules*, **2022**, 27,	4.8	1
68	Nanobodies as molecular imaging probes.. *Free Radical Biology and Medicine*, **2022**,	7.8	0

67	Development and comparison of three Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study.. *European Journal of Nuclear Medicine and Molecular Imaging*, **2022**, 1	8.8	0
66	AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model.. *EMBO Molecular Medicine*, **2022**, e09824	12	2
65	Chemoenzymatic synthesis of 6?-sialolactose-modified nanobody. *Journal of Carbohydrate Chemistry*, 1-15	1.7	
64	Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era.. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, **2022**, e1785	9.2	2
63	Llamanade: An open-source computational pipeline for robust nanobody humanization.. *Structure*, **2021**,	5.2	1
62	Structure-based design and construction of a synthetic phage display nanobody library.. *BMC Research Notes*, **2022**, 15, 124	2.3	0
61	Single-Domain Antibodies for Targeting, Detection, and Imaging of Human CD4 Cells.. *Frontiers in Immunology*, **2021**, 12, 799910	8.4	0
60	Nanobodies: from structure to applications in non-injectable and bispecific biotherapeutic development.. *Nanoscale*, **2022**, 14, 7110-7122	7.7	0
59	AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System.. *Frontiers in Neurology*, **2022**, 13, 870799	4.1	
58	DataSheet_1.pdf. **2020**,		
57	Data_Sheet_1.docx. **2019**,		
56	Image_1.pdf. **2019**,		
55	Image_2.pdf. **2019**,		
54	Image_3.pdf. **2019**,		
53	Table_1.pdf. **2019**,		
52	Table_2.pdf. **2019**,		
51	Table_3.pdf. **2019**,		
50	Antibody-Recruitment as a Therapeutic Strategy: A Brief History and Recent Advances.. *ChemBioChem*, **2022**,	3.8	0

49	Nanobody-based CAR-T cells for cancer immunotherapy.. *Biomarker Research*, **2022**, 10, 24	8	2
48	Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	1
47	Advances in antibody phage display technology.. *Drug Discovery Today*, **2022**,	8.8	4
46	Nanobodies in the limelight: Multifunctional tools in the fight against viruses.. *Journal of General Virology*, **2022**, 103,	4.9	
45	Emerging applications of nanobodies in cancer therapy. *International Review of Cell and Molecular Biology*, **2022**,	6	0
44	Peptide derived nanobody inhibits entry of SARS-CoV-2 variants.		
43	Current innovative engineered antibodies. *International Review of Cell and Molecular Biology*, **2022**,	6	
42	Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure. *Nature Communications*, **2022**, 13,	17.4	0
41	Preparation and identification of a single domain antibody specific for adenovirus vectors and its application to the immunoaffinity purification of adenoviruses. *AMB Express*, **2022**, 12,	4.1	
40	Combining of synthetic VHH and immune scFv libraries for pregnancy-associated glycoproteins ELISA development. *Applied Microbiology and Biotechnology*,	5.7	0
39	IgG-Binding Nanobody Capable of Prolonging Nanobody-Based Radiotracer Plasma Half-Life and Enhancing the Efficacy of Tumor-Targeted Radionuclide Therapy. *Bioconjugate Chemistry*,	6.3	0
38	Characteristics and Research Progress of Single Domain Antibody from Shark. *Bioprocess*, **2022**, 12, 131-137	0.7	
37	Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers. *Frontiers in Immunology*, 13,	8.4	1
36	Radiotheranostic Agents in Hematological Malignancies. *Frontiers in Immunology*, 13,	8.4	0
35	Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen. *Journal of Thrombosis and Haemostasis*,	15.4	0
34	Intramuscular delivery of formulated RNA encoding six linked nanobodies is highly protective for exposures to three Botulinum neurotoxin serotypes. *Scientific Reports*, **2022**, 12,	4.9	0
33	Development and characterization of a camelid derived antibody targeting a linear epitope in the hinge domain of human PCSK9 protein. *Scientific Reports*, **2022**, 12,	4.9	0
32	Identification and Characterization of Specific Nanobodies against Trop-2 for Tumor Targeting. **2022**, 23, 7942		

31	Total Chemical Synthesis of a Functionalized GFP Nanobody.	
30	CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies. 13,	0
29	Research progress and applications of nanobody in human infectious diseases. 13,	0
28	Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. **2022**, 4, 100054	0
27	Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library. 13,	0
26	Single Domain Antibody application in bacterial infection diagnosis and neutralization. 13,	0
25	Molecular basis for thermal stability and affinity in a VHH : contribution of the framework region and its influence in the conformation of the CDR3.	0
24	Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models. **2022**, 5,	0
23	Biparatopic nanobodies targeting the receptor binding domain efficiently neutralise SARS-CoV-2. **2022**, 105259	0
22	Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections. **2022**, 10, 1789	0
21	Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors. 13,	1
20	Splice Variants of G Protein-Coupled Receptors Expressed in Cancers: Effective Targeting with Monoclonal Antibodies and Antibody-Like Scaffolds As Ligands Irrespective of the Pharmacological Status of Isoforms. **2022**, 1-45	0
19	Nanobody derived using a peptide epitope from the spike protein receptor-binding motif inhibits entry of SARS-CoV-2 variants. **2023**, 299, 102732	0
18	Screening and identification of an anti-PD-1 nanobody with antitumor activity.	0
17	Sensitive immunoassay of Legionella using multivalent conjugates of engineered VHHs.	0
16	Neutralizing antibody creation technologies: case of SARS-CoV-2. **2022**,	0
15	Nanobodies in cell-mediated immunotherapy: On the road to fight cancer. 14,	0
14	Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen induced exhaustion.	0

13	Innovative strategies to study epigenetic regulation and advance precision medicine. **2023**,	0
12	Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses. **2023**, 561, 216139	0
11	Nanobodies: Robust miniprotein binders in biomedicine. **2023**, 195, 114726	0
10	A robust method for the rapid generation of nanobodies.	0
9	T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts. 14,	0
8	Application Progress of the Single Domain Antibody in Medicine. **2023**, 24, 4176	0
7	A bispecific T´cell engager recruits both type 1 NKT and Vδ1Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies. **2023**, 4, 100961	0
6	Global parameter optimisation and sensitivity analysis of antivenom pharmacokinetics and pharmacodynamics.	0
5	Nanobodies: A Review of Generation, Diagnostics and Therapeutics. **2023**, 24, 5994	0
4	Increasing the melting temperature of VHH with the in silico free energy score. **2023**, 13,	0
3	Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies. **2023**, 7, 23-42	0
2	Fine Tuning Rigid Body Docking Results Using the Dreiding Force Field: A Computational Study of 36 Known Nanobody-Protein Complexes.	0
1	AbNatiV: VQ-VAE-based assessment of antibody and nanobody nativeness for engineering, selection, and computational design.	0